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Abstract
Machado-Joseph disease, also known as spinocerebellar ataxia type 3, is a fatal polyglutamine disease with no disease-
modifying treatment. The selective serotonin reuptake inhibitor citalopram was shown in nematode and mouse models to
be a compelling repurposing candidate for Machado-Joseph disease therapeutics. We sought to confirm the efficacy of
citalopram to decrease ATXN3 aggregation in an unrelated mouse model of Machado-Joseph disease. Four-week-old
YACMJD84.2 mice and non-transgenic littermates were given citalopram 8 mg/kg in drinking water or water for
10 weeks. At the end of treatment, brains were collected for biochemical and pathological analyses. Brains of
citalopram-treated YACMJD84.2 mice showed an approximate 50% decrease in the percentage of cells containing
ATXN3-positive inclusions in the substantia nigra and three examined brainstem nuclei compared to controls. No
differences in ATXN3 inclusion load were observed in deep cerebellar nuclei of mice. Citalopram effect on ATXN3
aggregate burden was corroborated by immunoblotting analysis. While lysates from the brainstem and cervical spinal
cord of citalopram-treated mice showed a decrease in all soluble forms of ATXN3 and a trend toward reduction of
insoluble ATXN3, no differences in ATXN3 levels were found between cerebella of citalopram-treated and vehicle-
treated mice. Citalopram treatment altered levels of select components of the cellular protein homeostatic machinery that
may be expected to enhance the capacity to refold and/or degrade mutant ATXN3. The results here obtained in a second
independent mouse model of Machado-Joseph disease further support citalopram as a potential drug to be repurposed for
this fatal disorder.
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Introduction
Machado-Joseph disease (MJD) or spinocerebellar ataxia type
3 (SCA3) is an adult onset polyglutamine (polyQ) disease and
the most common autosomal dominant ataxia worldwide [1,
2]. This disease is caused by an unstable expansion of a
(CAG)n tract in the ATXN3 gene encoding a polyQ repeat near
the C-terminus of the protein ataxin-3 (ATXN3) [3]. The
length of ATXN3 CAG repeat ranges from 12 to 44 triplets
in the general population, and from ~ 60 to 87 in affected
individuals [4, 5]. Gait ataxia and diplopia are commonly
the first described symptoms [6, 7], yet a clinical diagnosis
of MJD is usually assigned to individuals with progressive
cerebellar ataxia and pyramidal signs associated with a com-
plex clinical presentation that can also include extrapyramidal
signs and peripheral amyotrophy [7–9]. This heterogeneous
symptomatology mirrors widespread neuropathology in mul-
tiple systems mainly involving the cerebellum, brainstem,
substantia nigra, thalamus, basal ganglia, and spinal cord [7,
10, 11].
Development of disease-modifying drugs for MJD pa-
tients is an urgent, unmet need as treatments currently
offered to patients are merely symptomatic and palliative
[12]. Novel strategies and cellular targets for therapy have
emerged as understanding of the mechanisms leading to
neuronal dysfunction and degeneration in this disease be-
come clearer over time [13]. Approaches thus far have
focused on silencing mutant ATXN3 expression [14–19],
reducing the abundance of the mutant protein ATXN3
[20], decreasing ATXN3 cleavage [21, 22], activating au-
tophagy [23–26], and balancing energy buffering of cells
[27].
Using unbiased drug screens, our two laboratories in-
dependently identified two existing drugs acting in sero-
tonin signaling as candidates to be repurposed for
Machado-Joseph disease: the selective serotonin reuptake
inhibitor (SSRI) citalopram [28] and the atypical antipsy-
chotic aripiprazole [20]. Here, joining efforts, we sought
additional evidence to support increased serotonergic sig-
naling by citalopram treatment as a promising therapeutic
route for MJD. We previously showed that citalopram
reduced aggregation of mutant ATXN3, restored motor
function, and attenuated neuronal loss in CMVMJD135
(Q135) transgenic mice, which express a full-length iso-
form of ATXN3 containing an expanded polyQ tract with
135 glutamines [28].
In the current study, we test the ability of citalopram to
decrease ATXN3 aggregation in a second mouse model of
disease that more closely represents the human target: the
YACMJD84.2 (Q84) transgenic mice, which harbor the full-
length human ATXN3 disease gene, including all the regula-
tory regions, with an expansion size within the human disease
range [29].
Materials and Methods
Experimental Design
The study was conceived to test the efficacy of citalopram in
decreasing human mutant ATXN3 aggregation at the patho-
logical (primary outcome) and molecular (secondary out-
come) levels in brains of YACMJD84.2 (Q84) mice (C57Bl/
6 background) [29]. Assessment of efficacy of citalopram on
motor performance in Q84 mice was not a goal of this study.
We performed a 10-week in vivo trial using hemizygous Q84
mice. Mice were assembled randomly in two groups: one
received citalopram dissolved in drinking water, and the other
received drinking water (vehicle). We powered our study to
assess our primary and secondary outcomes. Based on previ-
ously documented ATXN3 levels assessed by immunoblot-
ting [20], sample size was calculated assuming a power of
0.99 and p < 0.05 (two-tailed) to achieve 50% ATXN3 reduc-
tion (n = 10). All experiments were performed at the
University of Michigan and slides with immunostained brain
slices were sent to the University of Minho for assessment of
intranuclear ATXN3 aggregation by a rater blinded to
treatment.
Q84 Mouse Genotyping
Genotyping was performed using DNA isolated from tail bi-
opsy at the time of weaning, as previously described [29]. The
ATXN3 CAG repeat size in Q84 mice (Supplementary
Tables 1 and 2) was determined at Laragen Inc. by gene frag-
ment analysis using primers hATAXN3forFam (5 ′
ACAGCAGCAAAAGCAGCAA) and hATAXN3rev (5′
CCAAGTGCTCCTGAACTGGT).
Treatment of Hemizygous Q84 Mice with Citalopram
All animal procedures were approved by the University of
Michigan Committee on the Use and Care of Animals
(Protocol PRO00006371). Q84 transgenic mice have been
maintained in individual ventilated cages under the same an-
imal husbandry since 2007. Q84 mouse colony was
backcrossed with C57Bl/6 mice (Jackson’s Laboratories) in
2014. Mice were housed in cages with corncob bedding and
enviropaks (Lab Supply) for enrichment with a maximum
number of five animals (range 3–5) and maintained in a stan-
dard 12-h light/dark cycle with food and water ad libitum.
Cages with hemizygous Q84 mice and accompanying wild
type littermates (wt) were randomly selected to receive either
bottles containing citalopram dissolved in drinking water or
vehicle alone (drinking water). Citalopram hydrobromide
(8 mg/kg) (CAS 59729-32-7, Lündbeck, Denmark) was orally
administered to a cohort of 10 Q84 (six males and four fe-
males) and eight wt mice (three males and five females), and
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regular drinking water was given to 10 Q84 (six males and
four females) and six wt mice (four males and two females)
(Supplementary Table 1). After 10 weeks of treatment, mice
were anesthetized with ketamine/xylazine, perfused
transcardially with cold PBS, and brains were collected. The
right hemisphere was post-fixed for 3 days at 4 °C in 4% PFA,
immersed in 30% sucrose/PBS, and sectioned on a sledge
microtome (SM200R Leica Biosystems). Free-floating
40-μm sagittal sections were collected and stored in cryopro-
tectant solution at − 20 °C. The left hemisphere was divided
into cervical spinal cord, brainstem, cerebellum, and forebrain
areas and saved at − 80 °C.
Immunostaining
Sagittal brain sections were subjected to antigen retrieval
and incubated using the Vector MOM immunodetection
kit (Vector Laboratories, Burlingame, CA, USA) whenev-
er a mouse primary antibody was used. Sections were
incubated with mouse anti-ataxin-3 (1H9) (1:1000;
MAB536 0 M i l l i p o r e , B i l l e r i c a , MA , USA ) .
Immunolabeling was detected by incubation with a bio-
tinylated anti-mouse antibody followed by ABC coupled
to horseradish peroxidase (Vector Laborator ies ,
Burlingame, CA, USA) and DAB substrate (Vector
Laboratories, Burlingame, CA, USA).
Slides with mouse brain slices immunostained for ATXN3
were coded and sent to the University of Minho where they
were imaged and assessed for ATXN3 aggregation using a
bright-field Olympus BX51 stereological microscope
(Olympus). Cells containing dark-brown intranuclear
ATXN3-positive inclusions in the pontine, facial, vestibular,
and deep cerebellar nuclei (DCN), as well as in the substantia
nigra compacta of vehicle- or citalopram-treated Q84 animals
(n = 6–8 mice for each condition, 1–4 slices per mouse) were
counted in the full depth of the slices and normalized for total
area using the Visiopharm integrator system software.
Western Blotting
Protein extracts from different mouse brain areas were
obtained by lysis in RIPA buffer containing protease in-
hibitors (Complete, Roche Diagnostics), followed by son-
ication and centrifugation. Supernatants (soluble protein
fractions) from the cervical spinal cord, brainstem, and
cerebellum were collected and total protein concentration
was determined using the BCA method (Pierce). Total
protein lysates from soluble fractions (100 μg from the
brainstem and cerebellum) were resolved on 10% SDS-
PAGE gels, and corresponding PVDF membranes were
incubated overnight at 4 °C with primary antibodies:
mouse anti-HSP70 (1:500; SPA810, Enzo Life Sciences),
rabbit anti-HSP90α (1:1000; ab2928, Abcam), mouse
ant i -HSP90β (1 :1000; ADI-SPA842, Enzo Life
Sciences), rabbit anti-HSP40 (1:1000; #4868, Cell
S igna l ing ) , mouse an t i -p62 /SQSTM1 (1 :1000 ;
H00008878-M01, Novus Biologicals), rabbit anti-
Beclin1 (1:1000; ab207612, Abcam), rabbit anti-LC3
(1:500; PM036, MBL International Corporation), mouse
anti-GAPDH (1:5000; MAB374, Millipore), and rabbit
anti-MJD [30] (1:30000). Bound primary antibodies were
visualized by incubation with a peroxidase-conjugated an-
ti-mouse or anti-rabbit secondary antibody (1:10000;
Jackson Immuno Research Laboratories) followed by
treatment with ECL-plus reagent (Western Lighting,
PerkinElmer) and exposure to autoradiography films.
Band intensity was quantified by densitometry using
ImageJ.
Filter Trap Assay
Pellets corresponding to insoluble protein fractions were
washed twice with RIPA buffer, resuspended in 300 μL of
Laemmli buffer 2×, sonicated during 30 s, and boiled at
100 °C for 15 min. After 20 min of centrifugation at
13000 rpm, the supernatant was collected and saved at
− 80 °C. Insoluble protein lysates were quantified and
loaded (50 μg for the cerebellum and brainstem, and
30 μg for the spinal cord) in a filter trap assay apparatus
containing a 0.20-μm acetate cellulose membrane
(Sterlitech) that was then incubated overnight with anti-
MJD (1:10000) at 4 °C.
Gene Expression Analysis
Total RNA from cervical spinal cords of vehicle or
citalopram-treated Q84 mice was extracted as previously
[20]. Total cDNAwas generated from 1 μg of total RNA per
sample using iScript™ cDNA synthesis kit (Bio-RAD).
Levels of human ATXN3, mouse Atxn3, and Gapdh tran-
scripts were assessed by quantitative real-time polymerase
chain reaction as previously [20].
Statistical Analysis
Levels of proteins and counts of cells containing ATXN3
intranuclear inclusions were compared using Student’s t
test (comparison of two groups) whenever distributions
were normal and homogeneous. In the other cases, com-
parisons were assessed using the non-parametric Mann-
Whitney U test. A P < 0.05 was considered statistically
significant in all analyses. Data were analyzed using
IBM SPSS Statistics 22 software.
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Results
Citalopram Reduces ATXN3 Intranuclear Inclusions
in Brainstem Nuclei and Substantia Nigra but Not
in Deep Cerebellar Nuclei (DCN) of Q84 Transgenic
Mice
This study builds on the discovery that citalopram decreases
ATXN3 intranuclear inclusions in diverse brainstem nuclei of
Q135 transgenic mice [28]. Here, we combined efforts to assess
the efficacy of citalopram in ameliorating ATXN3 aggregation in
brains of a second mouse model of MJD, the hemizygous Q84
mice [29]. While the mouse trial and all the molecular and im-
munostaining experiments were carried out at the University of
Michigan, imaging and counts of cells containing ATXN3
intranuclear inclusions were executed blindly to treatment at
theUniversity ofMinho. Cages containing 4-week-oldQ84mice
and wt littermates were randomly assigned to receive either a
bottle containing citalopram dissolved in drinkingwater (estimat-
ed concentration of 8mg/kg) or a bottle of regular drinkingwater
(vehicle) during 10 weeks (Fig. 1a, Supplementary Table 1). On
the last day of treatment, mouse brains were collected for protein
and pathological analyses (Fig. 1a). While all animals were in-
cluded in the experimental molecular and pathological assess-
ments, mice numbers 1, 2 and 17 were excluded from data anal-
yses as their main CAG repeat sizes were found to be approxi-
mately 10 repeats lower than those of the other mice
(Supplementary Table 1).
We first assessed the efficacy of citalopram in reducing
ATXN3 aggregation by counting cells that contained
ATXN3-positive intranuclear inclusions in brain regions
known to be affected in MJD patients [10, 31]. Brain sections
from citalopram-treated Q84 mice showed a significant de-
crease in cells containing ATXN3 intranuclear inclusions in
pontine, vestibular and facial nuclei, and substantia nigra
compacta to, respectively, 56%, 60%, 62%, and 71% of levels
found in controls (Fig. 1b). In contrast, no differences in
ATXN3 intranuclear inclusion load were observed in DCN
of mice from the two treatment groups (Fig. 1b). Thus, the
efficacy of citalopram in Q84 mice under these experimental
conditions appears to be region-selective, reducing ATXN3
aggregate pathology in various examined nuclei of the mid-
brain and hindbrain but not in the cerebellar nuclei.
Levels of All ATXN3 Protein Forms Are Decreased
in the Brainstem and Spinal Cord, but Not
Cerebellum, of Q84 Mice Treated with Citalopram
The pathological observation of a region-specific effect of
citalopram to reduceATXN3 aggregation inQ84mouse brains
was corroborated by protein analysis. Compared to controls,
protein lysates from the brainstem and cervical spinal cord of
citalopram-treated Q84 mice showed a decrease of all soluble
forms of human and mouse ATXN3 (Fig. 2a, b) and, respec-
tively, a trend toward reduction and significantly reduced in-
soluble ATXN3 (Fig. 2d, e). Efficacy of citalopram to reduce
ATXN3 seems to be downstream of gene transcription level as
abundance of human ATXN3 and mouse Atxn3 transcripts was
similar in the cervical spinal cords of vehicle and citalopram-
treated Q84 mice (Supplementary Fig. 1). Levels of soluble
and insoluble ATXN3 were unchanged in cerebellar lysates of
citalopram-treated mice (Fig. 2c, f). Treatment of wt littermate
mice with citalopram did not affect levels of endogenous
mouse Atxn3 in any of the abovementioned regions
(Supplementary Fig. 2).
Central Nervous System Areas of Q84 Mice Show
Differential Expression Patterns ofMajor Components
of Macroautophagy and Chaperone Machineries
As observed in a Caenorhabditis elegansmodel of MJD [28],
citalopram-mediated reduction of mutant ATXN3
aggregation/abundance in brains of transgenic mice of this
disease is probably mediated by components of serotonergic
signaling. Serotonin is known to modulate the protein quality
control (PQC) machinery by which cells clear misfolded pro-
teins to maintain homeostasis [32, 33]. PQC machineries that
help cells clearing misfolded proteins are often dysregulated
in proteinopathies contributing to the cellular dysfunction ob-
served in these diseases. While macroautophagy, the protea-
some, and the chaperone machinery have been shown to be
involved in the clearance of mutant ATXN3 [23–25, 34–41],
these cellular machineries have also been reported to be dys-
regulated in MJD patients and animal models of this disease
including the Q84 mice [20, 24, 25, 34, 42–44]. However, a
comprehensive evaluation of temporal/spatial dysregulation
of PQC machineries in MJD animal models, including the
Q84 mice, is still lacking.
Accordingly, we measured levels of major components
of macroautophagy (LC3, p62, and beclin-1) and the chap-
erone machinery (Hsp40, Hsp70, Hsp90α, and Hsp90β) in
the brainstem, cervical spinal cord, and cerebellum of Q84
and control mice of 12 weeks of age, which is close to the
age of mice included in the citalopram trial at end-stage
(14 weeks old).
We previously assessed levels of key molecular chaperones
in the brainstem of 12-week-old Q84 mice and wt littermates
(Supplementary Table 2) and observed increased Hsp90β and
decreased Hsp40 levels in Q84 brainstem [20]. Here, we eval-
uated the expression levels of molecular chaperones in two
other areas typically affected in MJD patients—the cerebel-
lum and cervical spinal cord—in the same cohort of Q84 and
control mice used in our previous study (Supplementary Table
2) [20]. Decreased levels of Hsp40 were found in all studied
areas of Q84 mice: 25% reduction in the spinal cord and a
trend toward a reduction in the cerebellum of Q84 mice
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compared to wt littermates (Fig. 3a, b). No other examined
chaperone showed different levels in the cerebellum of Q84
mice compared to littermate non-transgenic mice (Fig. 3b). In
the spinal cord, however, Hsp90α and Hsp90β were de-
creased in Q84 mice relative to controls (Fig. 3a). Hsp70
levels were unchanged in all three studied regions of Q84
mice (Fig. 3a, b).
Pro te in lysa tes f rom the same group of mice
(Supplementary Table 2) were also evaluated for abundance
of key players in macroautophagy. Whereas no changes of
p62, beclin-1, and different isoforms of LC3 were observed
in the spinal cord (Supplementary Fig. 3B), p62 and beclin-1
levels varied significantly in the brainstem and cerebellum of
Q84mice compared to controls: (i) increased p62 and beclin-1
levels, 13% and 15%, respectively, in the brainstem
(Supplementary Fig. 3A) and (ii) reduced p62 (20%) in the
cerebellum (Supplementary Fig. 3C).
In summary, the three affected areas in 12-week-old Q84
mice—the brainstem, spinal cord, and cerebellum—display
different patterns of dysregulation of the molecular chaperone
machinery and macroautophagy.
Citalopram-Treated Q84 Mice Show Region-Specific
Changes in the Abundance of Key Chaperones
and Macroautophagy Proteins
The above results showing altered components of the chaper-
one machinery and macroautophagy in brains of Q84 mouse
Fig. 1 Citalopram decreases ATXN3-positive intranuclear inclusions in
themidbrain and hindbrain of Q84mice. a Four-week-old Q84mice were
orally treated with citalopram ~ 8 mg/kg or drinking water (vehicle) for
10 weeks, when they were euthanized and brains were collected for path-
ological assessment and protein analysis. b Brain slices were immuno-
stained with anti-ATXN3 antibody (1H9) and cells containing ATXN3-
positive intranuclear (nuc.) inclusions (black arrowheads) were counted
in pontine nuclei, facial nuclei, vestibular nuclei, substantia nigra, and
deep cerebellar nuclei (DCN) (n = 6–8 mice per condition, 1–4 slices
per mouse). Graphs representing the quantification of cell count for each
region show a robust decrease in number of cells containing ATXN3
intranuclear inclusions in all regions of citalopram-treated Q84mice com-
pared to vehicle-treated mice, except for the DCN. Scale bar = 50 μm.
Bars represent the average percentage of cells with ATXN3 inclusions
relative to vehicle-treated Q84 mice (± SEM), *P < 0.05 and **P < 0.01,
normalized for total area using Visiopharm software
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led us to investigate whether citalopram treatment affected the
abundance of these proteins that could mediate the folding
and/or clearance of ATXN3. Citalopram treatment modulated
levels of key chaperones and macroautophagy proteins in Q84
mouse brains (Figs. 4 and 5). Among the assessed chaperones
(1) levels of Hsp90β were significantly decreased to 60% and
63%, respectively, of control levels in the brainstem and spinal
cord (Fig. 4a, b) and (2) Hsp40 was decreased to 64% of
control levels in cerebella of citalopram-treated mice (Fig.
4c). On the other hand, Q84 mice treated with citalopram
revealed increases of 18% of p62 in both the cerebellum and
spinal cord, and 37% of beclin-1 in the cerebellum relative to
vehicle-treated mice (Fig. 5b, c).
In summary, treatment of Q84 mice with citalopram for
10 weeks modulates levels of certain components of protein
homeostasis involved in the clearance/folding of misfolded
proteins.
Discussion
While no preventive therapy for MJD is yet available, our two
laboratories have independently identified available drugs act-
ing in the serotonin signaling pathway as potential candidates
to repurpose for this fatal disease [20, 28]. In particular, the
SSRI citalopram was shown to reduce the load of ATXN3
inclusions in brains of CMVMJD135 mice and ameliorate
the motor phenotype presented by these mice [28].
In this collaborative study, we confirmed that citalopram
administered pre-symptomatically is effective in reducing the
aggregation and abundance of ATXN3 in brains of a second
mouse model of MJD, the YACMJD84.2 (Q84), which
expresses the full human disease gene [29]. As in the earlier
trial performed in CMVMJD135 mice [28], we carried out a
chronic pre-symptomatic treatment of Q84 mice with
citalopram, though only for 10 weeks rather than 30 weeks.
As in the CMVMJD135 mice [28], citalopram given to Q84
mice before detectable intranuclear ATXN3 aggregation led to
a significant decrease in the accumulation of ATXN3-positive
intranuclear inclusions in several brainstem nuclei and spinal
cord. Citalopram treatment showed, however, different effects
on the levels of soluble mutant ATXN3 in the two mouse
models. While this SSRI was not effective in reducing levels
of soluble mutant ATXN3 in brainstems of CMVMJD135
mice [28], it led to a reduction in all forms of soluble mutant
human ATXN3 and mouse Atxn3 in the brainstem and spinal
cord of Q84 mice. This difference in citalopram treatment
effect between the two mouse models may be explained by
differences in the biochemical nature of mutant ATXN3 pro-
teins in brain extracts of Q84 and CMVMJD135 mice.
Whereas CMVMJD135 mouse brains express a single human
mutant ATXN3 isoform with a polyQ hyperexpansion (~ 135
glutamines) that is barely detectable in soluble extracts and
mostly forms insoluble intranuclear inclusions, Q84 brains
express several isoforms of easily detectable soluble and in-
soluble mutant ATXN3 with a polyQ expansion in the known
disease range (70–80 glutamines) [29, 35]. The efficacy of
citalopram to modulate the folding/ degradation of soluble
forms of mutant ATXN3 may be greater for the shorter, less
aggregation-prone polyQ lengths found in Q84 mice. Indeed
citalopram decreased levels of endogenous mouse Atxn3 in
the brainstem and spinal cord of Q84 mice suggesting that
citalopram modulates pathways that clear both human and
mouse ATXN3 in these two brain regions. Further evidence
that supports the existence of common clearance mechanisms
of human and mouse ATXN3 that are impaired in Q84 brains
comes from the fact that mouse Atxn3 in Q84 brainstems is
increased to about 270% of wt levels (Supplementary Fig. 4)
[20].With the potential effect of citalopram at the transcription
level excluded, this SSRI may then improve the function of
such protein control mechanisms and promote a better folding
of mutant ATXN3 and clearance of both human and mouse
ATXN3 in specific brain regions of Q84 mice.
Like the brainstem and spinal cord, the cerebellum shows a
high degree of degeneration in MJD patients, particularly in
the DCN [6, 31]. For successful translation to patients afflicted
with MJD, citalopram ideally will ameliorate signs of this
disease in the cerebellum as well as the brainstem and spinal
cord. In CMVMJD135 mice treated for 30 weeks, citalopram
had a positive effect in the cerebellum by restoring cerebellar
calbindin staining [28] although it is unknown if it reduced
cerebellar ATXN3 aggregation. Further evidence of efficacy
of citalopram in the cerebellum of CMVMJD135 mice comes
from the fact that mice treated post-symptomatically for
17 weeks not only showed restoration of calbindin levels but
Fig. 2 ATXN3 levels are reduced in the brainstem and spinal cord but not
the cerebellum of Q84 mice treated with citalopram. a, b Anti-ATXN3
immunoblotting of soluble protein extracts shows decreased HMW
ATXN3, mutant human ATXN3, and endogenous mouse ATXN3 abun-
dance in the brainstem of citalopram-treated mice (numbers 11–20) com-
pared to vehicle-treated mice (numbers 1–10) (males 1–6 and 11–16;
females 7–10 and 17–20). b Soluble protein extracts from spinal cord
also show decrease levels of all forms of ATXN3. c Soluble proteins from
cerebella of the samemice do not reveal any difference between treatment
groups. Graphs show quantification of protein bands by densitometry.
Bars represent the average percentage of protein species relative to
vehicle-treated mice, corrected for Gapdh (± SEM). d, e Filter trap assay
shows a trend toward reduction of insoluble ATXN3 in brainstem (P =
0.232) and in the spinal cord (P = 0.095) of citalopram-treated mice. f No
differences in insoluble ATXN3 were found for cerebellar lysates (P =
0.421). Bars in the graph represent the average level of insoluble ATXN3
relative to vehicle-treated mice (± SEM). Statistical significance is indi-
cated as *P < 0.05, **P < 0.01, and ***P < 0.001. Black circles indicate
mice, whose results were excluded from statistical analysis because they
harbored significantly lower CAG repeat numbers compared with the
average (CAG)n of the mouse group. Gray circle represents a mouse
whose band density was excluded from statistical analysis for being po-
sitioned in the last lane of the gel and consequently of unreliable value
due to technical reasons
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also a decrease in ATXN3 intranuclear aggregates in the DCN
[45]. In the present study, however, citalopram treatment for a
shorter time period (10 weeks) did not lead to a reduction in
the cerebellar load of ATXN3 intranuclear inclusions or
ATXN3 soluble or insoluble forms in Q84 mice. A follow-
up trial in which Q84 mice are subjected to prolonged treat-
ment with this SSRI beyond 10 weeks would answer whether
our failure to see an effect in the cerebellum is due to the
limited duration of treatment.
The divergent impact of citalopram treatment on vari-
ous brain regions may depend on the degree of regional
neuropathology and disease severity at a given time point.
We observed that the brainstem, cervical spinal cord, and
cerebellum of 12-week-old Q84 mice differ in the state of
dysregulation of major components of macroautophagy
and chaperone machinery. For example, while reduced
amount of Hsp40 was a common signature to all three
studied brain regions, changes in the abundance of cyto-
plasmic forms of Hsp90 in Q84 mice were confined to the
brainstem and spinal cord. Whereas Hsp90β was increased
in the brainstem [20], both Hsp90α and Hsp90β were
decreased in the cervical spinal cord of Q84 mice.
Others and us have previously shown that decreased abun-
dance of Hsp90, or its inhibition by 17-DMAG, correlates
directly with reduction of mutant ATXN3 levels and improve-
ment of pathological and motor phenotypes in animal models
of MJD [20, 35, 46, 47]. Indeed, in this pre-clinical trial of
citalopram in Q84 mice, we confirmed the existence of a di-
rect correlation of HMW species of ATXN3 to Hsp90β abun-
dance in the brainstem and spinal cord (Supplementary
Fig. 5A, B). These results suggest that modulation of seroto-
nergic signaling by citalopram regulates specific components
Fig. 3 Twelve-week-old Q84 mice show decreased levels of key
molecular chaperones in the spinal cord but not cerebellum compared
to wt littermates. Western blot analysis of total soluble protein lysates
from spinal cords of Q84 mice show decreased levels of Hsp90α,
Hsp90β, and Hsp40 relative to controls (a). No significant changes
were observed for any assessed chaperones in cerebellar extracts of
Q84 mice (b). a, b Left panels show immunoblots of indicated proteins
in soluble fractions of spinal cord or cerebellum from Q84 and control
littermates (Supplementary Table 2). Right panels show graphs
representing the quantification of protein bands by densitometry. Bars
represent the average percentage of protein species relative to wt mice,
corrected for Gapdh (± SEM). Statistical significance is indicated as *P <
0.05 and **P < 0.01
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of protein homeostasis that could help the folding and/or clear-
ance of toxic ATXN3. In particular, this study provides
strengthening evidence that Hsp90, mainly the constitutive
form Hsp90β, could represent a therapeutic target for MJD.
The efficacy of citalopram in reducing mutant ATXN3 ag-
gregation in brains of CMVMJD135 [28] and Q84 mice (this
study) when administered pre-symptomatically appears to be
greater than was observed in CMVMJD135 mice treated after
the onset of motor symptoms [45]. Together, these studies
suggest that treatment with citalopram or perhaps other
SSRIs in MJD might be most effective if initiated at early
stages of disease.
This study (1) confirms the efficacy of an approved drug,
citalopram, in decreasing ATXN3 aggregation in an
Fig. 4 Citalopram reduces levels of Hsp90β in the brainstem and spinal
cord and abundance of Hsp40 in the cerebellum of Q84 mice.
Citalopram-treated mice show significantly decreased levels of Hsp90β
in brainstem (a) and spinal cord (b) extracts, and reduced amount of
Hsp40 in cerebellar lysates (c). a, b, c Left panels show immunoblots of
indicated proteins in soluble fractions of the brainstem, spinal cord, and
cerebellum. Right panels display quantification of band intensity, with
values normalized to Gapdh. Bars represent the average percentage of
protein relative to vehicle-treated mice (± SEM). Statistical significance is
indicated as **P < 0.01. Mice 1, 2, and 20 were excluded from statistical
analysis
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independent mouse model of MJD; (2) supports the view that
various brain regions, and perhaps specific types of central
nervous system (CNS) cells, respond differently to mutant
ATXN3-mediated toxicity, and (3) underscores the
Fig. 5 Q84 mice treated with citalopram reveal slight alterations of
macroautophagy components in spinal cord and cerebellum.
Assessment of macroautophagy markers shows increased levels of p62
in the spinal cord (b), and of p62 and beclin-1 in the cerebellum (c) of
citalopram-treated mice compared to controls. Citalopram treatment did
not affect levels of LC3 in any of the three regions (a–c). a, b, c Left
panels show immunoblots of indicated proteins in soluble fractions of the
brainstem, spinal cord, and cerebellum. Right panels display quantifica-
tion of band intensity, with values normalized to Gapdh. Bars represent
the average percentage of protein relative to vehicle-treated mice (±
SEM). Statistical significance is indicated as *P < 0.05 and **P < 0.01.
Mice 1, 2, and 20 were excluded from statistical analysis. Diamond (♦)
represents p62 bands
Mol Neurobiol
importance of evaluating the efficacy of citalopram, or other
future therapeutic agents, in all brain regions affected in the
disease.
While the current study does not establish a role for the
treatment of Machado-Joseph disease patients with
citalopram, our confirmation of this drug’s efficacy in reduc-
ing ATXN3 pathology in a second rodent model of disease,
coupled with its known safety record in humans, offers strong
support for future efforts to perform human clinical trials to
establish a role for citalopram, and possibly other SSRIs, in
the treatment of this severely impairing disease.
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